Trial Profile
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) With FLT3-ITD Mutations
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Cytarabine; Cytarabine; Daunorubicin liposomal; Etoposide; Fludarabine; Hydrocortisone; Methotrexate; Prednisolone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 16 Aug 2019 This trial has been Discontinued in Ireland.
- 08 May 2018 New trial record